Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche CD47 antibody start-up gives up-lays off all employees
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5358)
•••
Comment by Noteableon Oct 05, 2023 3:13pm
109 Views
Post# 35671723

RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employees

RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employeesOctober 05, 2023 - US clinical-stage immuno-oncology company ALX Oncology Holdings (Nasdaq: ALXO) saw its shares rocket 56% to $7.51 yesterday, as it announced positive clinical results for its lead asset after a previous disappointment. 

ALX announced positive prespecified interim Phase II data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the company’s CD47 blocking therapeutic, in combination with trastuzumab, Cyramza (ramucirumab) and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction (GEJ) cancer. 

The interim analysis revealed that patients receiving evorpacept in combination with other cancer drugs had a 52% overall response rate. This was a significant improvement compared to the 22% response rate observed in the control group, which did not receive evorpacept.  

In addition, ASPEN-06 is the first global randomized study in HER2-positive gastric cancer where prior Keytruda (pembrolizumab) and Enhertu were allowed. 

https://www.thepharmaletter.com/article/alx-oncology-soars-on-phase-ii-results-of-evorpacept-in-gastric-cancer


 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities